Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-11

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

NCT05753722

Advanced or Metastatic Solid Tumors Non Small Cell Lung Cancer NSCLC

RECRUITING PHASE1

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

NCT05763004

Solid Tumor, Adult

RECRUITING PHASE1

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

NCT05054348

Solid Tumor, Adult

COMPLETED PHASE1

An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

NCT04443088

Cancer Solid Tumor, Adult Cancer Metastatic +3 more

ACTIVE_NOT_RECRUITING PHASE1

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

NCT07124117

Advanced Solid Tumor

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1, open-label, multicenter, dose-escalation and dose-expansion study of IO-202 in adult subjects with advanced relapsed or refractory solid tumors to study safety, tolerability, pharmacokinetic, pharmacodynamics and clinical activity of IO-202 as monotherapy or in combination with pembrolizumab and to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD), and to select the RP2D.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IO-202 Monotherapy (dose escalation)

Group Type EXPERIMENTAL

IO-202

Intervention Type BIOLOGICAL

IO-202 given as monotherapy

IO-202 dose escalation + pembrolizumab

Increasing dose levels of IO-202 with fixed dose of pembrolizumab

Group Type EXPERIMENTAL

IO-202 + pembrolizumab combination therapy

Intervention Type BIOLOGICAL

IO-202 and fixed dose pembrolizumab combination therapy

IO-202 + pembrolizumab combination therapy (dose expansion)

RP2D + pembrolizumab combination therapy in solid tumor cohorts

Group Type EXPERIMENTAL

RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types

Intervention Type BIOLOGICAL

Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IO-202

IO-202 given as monotherapy

Intervention Type BIOLOGICAL

IO-202 + pembrolizumab combination therapy

IO-202 and fixed dose pembrolizumab combination therapy

Intervention Type BIOLOGICAL

RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types

Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IO-202 + Keytruda combination therapy RP2D of IO-202 + Keytruda combination therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must be ≥18 years old.
2. Part 1 - Dose Escalation: Subject must have any histologically or cytologically confirmed advanced or metastatic solid tumor and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinical benefit.
3. Part 2 - Dose Expansion: Subject must have failed at least one available therapy for the disease under study.
4. Subject must have measurable disease per RECIST 1.1 as assessed by local clinical site.
5. Subject must have an Eastern Cooperative Oncology Group performance status of 0 or 1.

Exclusion Criteria

1. Subject who previously received leukocyte immunoglobulin-like receptor subfamily B (LILRB) or immunoglobulin-like transcript \[ILT\]) targeting agents including those targeting LILRB1 (ILT2), LILRB2 (ILT4), LILRB4 (ILT3), or leukocyte-associated immunoglobulin-like receptor 1 (LAIR1).
2. Subject who received a biologic systemic anti-cancer therapy \<4 weeks or 5 half-lives prior to their first day of study drug administration, or a small molecule systemic anti-cancer therapy or definitive radiotherapy \<2 weeks or 5 half-lives prior to their first day of study drug administration or have not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or better from any adverse events (AEs) that were due to prior cancer therapeutics.
3. Subject has symptomatic central nervous system (CNS) tumor.
4. Requires systemic corticosteroids at a dose of \>10 mg prednisone or the dose equivalent of other systemic corticosteroid.
5. History of radiation pneumonitis, non-infectious pneumonitis or interstitial lung disease.
6. History of Grade ≥3 immune-related AEs with any prior immunotherapy.
7. Subjects with known hypersensitivity to any of the components of the IO-202 formulation or pembrolizumab.
8. Active known malignancy with the exception of any of the following:

1. Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer;
2. Low-risk prostate cancer for which observation or hormonal therapy only is indicated;
3. Any other malignancy treated with curative intent with the last treatment completed ≥ 6 months before study initiation (with the exception of hormonal therapies when indicated).
9. Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) or left ventricular ejection fraction (LVEF) \<40% by ECHO or multi-gated acquisition (MUGA) scan ≤28 days prior to Cycle 1 Day 1 (C1D1).
10. Any of the following in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, clinically significant arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch block or controlled atrial fibrillation are allowed.
11. Ongoing cardiac dysrhythmias of Grade 2 or higher per NCI CTCAE, Version 5.0.
12. Active bacterial, viral, and/or fungal infection including hepatitis B (HBV), hepatitis C, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or acquired immunodeficiency syndrome (AIDS)-related illness.
13. Subjects with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before study entry.
14. Subject with current active treatment in another interventional therapeutic clinical study.
15. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No